

Relationship between eNOS 894G>T polymorphism and the antihypertensive efficiency of two dihydropyridine calcium channel blocker drugs, azelnidipine and nitrendipine, in Chinese EH patients

Zhiying Luo, Fazhong He, Jianquan Luo, Wei Zhang

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China

Email address:

yjsd2003@163.com (Wei Zhang)

To cite this article:

Zhiying Luo, Fazhong He, Jianquan Luo, Wei Zhang. Relationship between eNOS 894G>T Polymorphism and the Antihypertensive Efficiency of Two Dihydropyridine Calcium Channel Blocker Drugs, Azelnidipine and Nitrendipine, in Chinese EH Patients. *American Journal of Life Sciences*. Special Issue: Pharmacogenomics & Personalized Medicine. Vol. 3, No. 1-4, 2015, pp. 1-6. doi: 10.11648/j.ajls.s.2015030104.11

Abstract: *Background:* Dihydropyridine calcium-channel blockers (dCCBs) were widely used in anithypertensive treatment. The aim of this study was to examine the effect of polymorphisms of CACNA1C, eNOS and RGS2 on the antihypertensive efficiency of dihydropyridine calcium channel blocks (dCCBs) in Chinese patients with essential hypertension (EH). *Methods:* A total of 107 untreated Chinese mild to moderate EH patients were enrolled in this study, and had been prescribed azelnidipine or nitrendipine as monotherapy. All patients who had gave informed consent for genetic research were divided into two groups: treated with azelnidipine or nitrendipine for at least 6 weeks. Five polymorphisms of three blood pressure (BP) and hypertension susceptible genes were studied in our research, and these polymorphisms were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct sequencing. Every patients' BP and heart rate were measured at 0 week, 2 weeks, 4 weeks and 6 weeks. The biochemical parameters of blood were detected before and 6 weeks after the administration. Adverse effects were evaluated at the last visitation. *Results:* Both the systolic and diastolic BP levels were significantly decreased after six weeks of dCCBs treatment, from 149.3 ± 9.2 mmHg to 132.2 ± 11.7 mmHg and from 97.9 ± 3.0 mmHg to 85.5 ± 7.5 mmHg, as well as the levels of TP, TBIL, CHO and LDL, the P-values were $P=0.017$, $P=0.045$, $P=0.039$, $P=0.041$ respectively. As 11 of 75 patients appeared adverse reactions, the rate of adverse effects showed no difference in various genotypes. There were significant interactions between eNOS G894T polymorphism and Δ DBP, Δ MBP on azelnidipine therapy patients, but not in nitrendipine, the GG genotype carriers were more sensitive in blood decrease than GT/TT genotype carriers ($P<0.05$). *Conclusion:* CCBs had potential hepatoprotective and antiatherosclerosis effects for Chinese EH patients. And the eNOS G894T polymorphism is associated with the hypotensive effect of azelnidipine.

Keywords: Hypertension, Calciumchannel Blockers, Zelnidipine, Nitrendipine, eNOS, Polymorphism

1. Introduction

Hypertension, which is considered to be present when at least two times subsequent measurement of systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg, is a critical risk factor for cardiovascular diseases and blood pressure (BP) control in hypertensive patients is the most effective intervention for reducing cardiovascular diseases risk^[1]. Although one in six Chinese adults have been bitterly suffered from hypertension, the awareness, treatment and control rate of hypertension is relatively low in China^[2].

Calcium-channel blocker drugs (CCBs), especially the dihydropyridine (dCCBs) subclass, are widely used in the treatment of essential hypertension (EH)^[3,4]. As we known, the antihypertensive response rate of patients to dCCBs monotherapy is just a little above 50% in stage I or II hypertension patients; however, there are not reliable predictors to predict the hypotensive efficiency of dCCBs^[5]. Previous researches have evidenced that gender is not an important factor to antihypertensive effect of CCBs when compared with age and initial BP; moreover, genetic factors can significantly influence the antihypertensive sensitivity of CCBs^[6-9].

The $\alpha 1C$ subunit of the L-type calcium channel (CACNA1C) is involved in encoding the drug target of CCBs, the polymorphisms of which are widely recognized to be the most critical genetic factor of the response of dCCBs^[10-12]. The key DHP-sensing residues of CACNA1C are defined in transmembrane segments IS6, IIS5, IIS6, IVS6 and the pore helix IIIP^[5, 13]. By screening the data of HapMap website, we find that a mutation in the IS6, CACNA1C 1391L (rs1051256), has never been studied before. And another mutation (rs2239101) was found associated with SBP in a genome-wide association meta-analysis study^[14].

Endothelial nitric oxide synthase (eNOS) is a limiting-velocity factor in producing nitric oxide (NO). Both clinical and animal studies have suggested that abnormal NO synthesis is involved in the pathogenesis of hypertension^[15, 16]. Previous article has proved that dCCBs can up-regulate eNOS gene expression in brain and further lower BP by increasing the production of NO^[17]. Some studies also have mentioned that polymorphism of eNOS G894T associated with the complex pathogenesis of EH^[18, 19], NO production deficiency^[20] and also played an important role in resistance to the conventional antihypertensive therapy^[21].

Regulator of G-protein signaling 2 (RGS2), a protein of the RGS family, mediates the actions of many important vasoconstrictors by interfering with signaling through receptors that couple to G α subclass of G proteins^[22]. Reduced RGS2 expression contributes to resistance to antihypertensive agents through poor negative feedback on the effects of aldosterone and of other vasoactive agents^[23]. Recently, a report showed that A-638G polymorphism of RGS2 could affect the therapeutic performance of Azelnidipine^[24]. And there are evidences that two common mutations of RGS2, RGS2 1891-1892del TC (rs3053226)^[24], and C1114G (rs4606) is respectively associated with hypertension and RGS2 expression^[25].

The purposes of our study is to investigate the influence of genetic polymorphisms of CACNA1C (rs1051356, rs2239101), eNOS (rs1799983), and RGS2 (rs3053226, rs4606) on the antihypertensive efficiency of dCCBs in Chinese Han EH patients.

2. Methods

2.1. Subjects

The protocol of this research was approved by the Ethics Committee of Xiangya hospital. We enrolled 107 EH patients, according to the inclusion and exclusion criteria, but only 75 patients returned visit on time. Peripheral blood samples for genetic analysis were collected after signature of informed consent. All of the subjects were untreated before and had been prescribed dCCBs as monotherapy. The clinical data could be obtained from records of 4 consecutive outpatient visits before and after 2 weeks, 4 weeks and 6 weeks of treatment. Blood pressure and heart rate were measured by trained nurses in quiet conditions after the patients had rested at least 10 minutes. Automatic blood pressure monitor with

intellisense was used in our study. Both the systolic blood pressure (SBP) and diastolic blood pressure (DBP) were the results of the means of 3 times measurements in 10 minutes. The patients who took azelnidipine were 8 mg/day (50/75) or 10 mg nitrendipine every day (25/75).

The biochemical parameters of blood were evaluated before and 6 weeks after the administration, which including four liver function related indexes (total protein, albumin, total bilirubin and glutamic-pyruvic transaminase), three renal function related indexes (blood urea, serum creatinine and serum uric acid), four lipid level related indexes (triglyceride, total cholesterol, high-density lipoprotein, low-density lipoprotein) and fasting blood-glucose. And the adverse effects were evaluated by clinical doctors at the last return visitation. The adverse effects investigated in this study included respiratory adverse reactions (cough, respiratory syndrome), common cardiovascular system adverse reactions (palpitation, edema and orthostatic hypotension), common gastrointestinal system adverse reactions, common adverse reactions of the skin and common adverse reactions of the nervous system (dizziness).

2.2. Inclusion and Exclusion Criteria

Inclusion criteria: men or women; diagnosed with EH, confirmed with two or more times BPs, SBP > 140 mm Hg or DBP > 90 mm Hg; never received antihypertensive therapy before; with entire 6 weeks of clinical follow up date and blood sample.

Exclusion criteria were secondary hypertension, heart failure, myocardial infarction, stroke, renal or liver dysfunction, malignant tumor or taking any medication that would further affect BP during CCBs monotherapy.

2.3. Genotyping

The polymerase chain reaction (PCR) was performed using oligonucleotide primers, which were designed based on published gene sequence and synthesized by Invitrogen Trading (Shanghai) Co., Ltd. The PCR reactions were carried out with a total volume of 25 μ L, the reaction mixture contains as follows: 2.5 μ L 10 \times dNTPs (2.5 μ M each), 2.5 μ L 10 \times PCR buffer, 0.5 μ L both forward and reverse primers, 0.3 μ L Taq DNA polymerase (5U/ μ L), 1.0 μ L of genomic DNA sample and 17.7 μ L of PCR grade water. All the PCR reaction processes forenamed were carried out with the silver tank PCR instrument (Eppendorf AG, Germany). All of the digestion enzymes for the PCR products were designed according to the criteria.

The genotypes of CACNA1C (rs1051356, rs2239101), eNOS (rs1799983) were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and the restriction enzymes are HpyF31, BsuRI, and MboI respectively. Genotypes of RGS2 (rs3053226, rs4606) were directly sequenced by Shanghai Majorbio company. The genotype results of PCR-RFLP were verified by sanger sequencing.

2.4. Statistical Analysis

Statistical analyses were performed using SPSS ver. 19.0, measurement data results are expressed as the mean \pm SD. Baseline characteristics between different groups were analyzed with ANOVA. Hardy-Weinberg equilibrium was evaluated by Pearson's χ^2 test, allele-frequencies were determined by gene counting. Comparison of BP variance between genotypes was performed with multivariate analysis of variance (MANOVA), adjusting for confounding factors, which including aging, sex and BMI. A two-tailed P-value <0.05 was considered statistically significant.

3. Result

3.1. Antihypertensive Effects of dCCBs in EH Patients

As showed in Table 1, both the systolic and diastolic blood pressure levels were significantly decreased after six weeks of dCCBs treatment, from 149.3 ± 9.2 mmHg to 132.2 ± 11.7 mmHg and from 97.9 ± 3.0 mmHg to 85.5 ± 7.5 mmHg respectively, (both P-values were lower than 0.000). No significant change was observed in the levels of heart rate after 6 weeks treatment. After compare the biochemical parameters of blood before and after antihypertensive treatment, we found the TP level (74.2 ± 4.9 mg/dL and 70.9 ± 4.6 mg/dL before and after the treatment; $P=0.017$), TBIL level (15.6 ± 5.3 mg/dL and 13.9 ± 4.7 mg/dL before and after treatment; $P=0.045$), CHO level (5.4 ± 1.1 mg/dL and 5.0 ± 1.0 mg/dL before and after treatment; $P=0.039$) and LDL level (3.1 ± 0.8 mg/dL and 2.8 ± 0.8 mg/dL before and after treatment; $P=0.041$) decreased by big margin. Both three renal function indexes and FBG had no significant change ($P > 0.05$).

3.2. Genotypic analysis

The genotypes of 5 mutations of the three genes were successfully determined in the study population. The allelic frequencies and genotype distributions of the patients were presented in Table 2. In our study population, two genotype frequencies of RGS2 gene (rs3053226 and rs4606) in this study population were not accorded with Hardy-Weinberg equilibrium, P-values were 0.768, 0.9191 and 0.855 respectively. So, we did not take these two SNPs of RGS2

into consideration in the further investigation.

3.3. Adverse Effects after dCCB Drugs Treatment

The adverse effects were evaluate after patients taken at least six weeks of CCBs hypotension treatment. Six of 75 patients appeared dizziness symptom (2 of nitrendipine group and 4 of azelnidipine group), 3 patients of azelnidipine showed cardiovascular adverse reactions and 2 patients of azelnidipine group had respiratory adverse reactions. The incidences of adverse effects showed no significant difference between azelnidipine (14%) and nitrendipine (8%) groups ($P>0.05$). We further compare the rate of adverse effects in different genotypes, and we did not found statistic relationship between the occurrence of adverse effects and gene polymorphisms, (all P-values >0.05).

3.4. Pharmacogenetics Study of Antihypertensive Efficiency of dCCB Drugs and Gene Polymorphisms

After analysis the relationship between these gene polymorphisms and the change of BP at each time point (2, 4, 6 weeks), we found only the polymorphism of the eNOS (G894T) showed a significant association with the change of BP (Δ BP: BP at 6 week – BP at 0 week). The eNOS 894GG genotype carriers had much more decrease of DBP and MBP than 894GT/TT genotype carriers (Δ SBP: GG -18.92 ± 11.32 mmHg, GT/TT -13.78 ± 5.69 mmHg, $P = 0.104$; Δ DBP: GG -13.78 ± 5.69 mmHg, GT/TT -8.85 ± 9.02 mmHg, $P = 0.008$; Δ MBP: GG -15.49 ± 6.61 mmHg, GT/TT -10.37 ± 10.55 mmHg, $P=0.018$). After adjustment for gender, age and BMI, the P-values for Δ SBP, Δ DBP and Δ MBP were 0.23, 0.012 and 0.031 between GG and GT/TT genotype carriers respectively as shown in Figure 1. Interestingly, after examined the effect of genetic factors in different drug groups, the relationship between eNOS G894T polymorphism and BP decrease only showed in azelnidipine, but not in subject with nitrendipine, as shown in Table 3. (Δ SBP: GG -16.2 ± 8.9 mmHg, GT/TT -9.5 ± 13.0 mmHg, $P = 0.073$; Δ DBP: GG -12.5 ± 5.1 mmHg, GT/TT -5.0 ± 7.6 mmHg, $P = 0.001$; Δ MBP: GG -13.7 ± 5.0 mmHg, GT/TT -6.5 ± 9.1 mmHg, $P=0.002$). There was no gene polymorphisms had relationship with the change of heart rate and the biochemical parameters of blood or adverse effects.

Table 1. BP, heart rate and biochemical parameters of blood change after antihypertensive treatment.

Variables	Pre-treatment	Post-treatment	P
SBP (mmHg)	149.3 \pm 9.2	132.2 \pm 11.7*	0.000
DBP (mmHg)	97.9 \pm 3.0	85.5 \pm 7.5*	0.000
Heart Rate	72.7 \pm 7.2	71.5 \pm 6.9	0.276
Liver function indexes			
Total protein (TP) (mg/dL)	74.2 \pm 4.9	70.9 \pm 4.6	0.017
Albumin (ALB) (mg/dL)	43.1 \pm 2.9	42.0 \pm 2.9	0.842
Total bilirubin (TBIL) (mg/dL)	15.6 \pm 5.3	13.9 \pm 4.7	0.045
Glutamic-pyruvic transaminase (ALT) (U/L)	26.3 \pm 12.4	25.2 \pm 15.4	0.501
Renal function			
Blood urea (BU) (mg/dL)	5.1 \pm 1.3	5.0 \pm 1.1	0.639
Serum creatinine (Scr) (mg/dL)	74.5 \pm 17.3	74.6 \pm 15.8	0.983
Serum Uric Acid (UA) (mg/dL)	314.7 \pm 67.4	318.9 \pm 63.3	0.796
Blood glucose level			
Fasting blood-glucose (FBG) (mg/dL)	5.4 \pm 1.3	5.4 \pm 1.2	0.786


Variables	Pre-treatment	Post-treatment	P
Blood lipid levels			
Triglyceride (TG) (mg/dL)	1.9±1.4	2.0±1.4	0.627
Total cholesterol (CHO) (mg/dL)	5.4±1.1	5.0±1.0	0.039
High-density lipoprotein (HDL) (mg/dL)	1.5±0.3	1.4±0.4	0.255
Low-density lipoprotein (LDL)	3.1±0.8	2.8±0.8	0.041

Table 2. Allelic frequency and genotype frequency distribution of *eNOS*, *RGS2*, *CACNA1C* in EH patients.

gene	SNP	genotype	Frequency number (%)	Allele frequency	P (H-W)
<i>eNOS</i>	Rs1799983	GG	52(74.3%)	G (86.4%)	0.77
		GT	17(24.3%)	T (13.6%)	
		TT	1(1.4%)		
<i>CACNA1C</i>	Rs2239101	TT	55(78.6%)	T (88.6%)	0.92
		CT	14(20.0%)	C (11.4%)	
		CC	1(1.4%)		
<i>CACNA1C</i>	rs1051356	AA	67(95.7%)	A (97.9%)	0.85
		AT	3(4.3%)	T (2.1%)	
		TT	0(0%)		
<i>RGS2</i>	rs3053226	DD	8(11.9%)	D (44.0%)	0.013
		DI	43(64.2%)	I (56.0%)	
		II	16(23.9%)		
<i>RGS2</i>	Rs4606	CC	9(12.9%)	C (46.4%)	0.0034
		CG	47(67.1%)	G (53.6%)	
		GG	14(20%)		

Table 3. Stratified analyses of the different hypotensive effects between *eNOS* G894T genotype and dCCBs interaction.

Variables	GG-azelnidipine			GT/TT-azelnidipine			P (GG versus GT/TT)		
	2W (38)	4W (38)	6W (36)	2W (9)	4W (9)	6W (9)	2W	4W	6W
Vist (N)									
ΔSBP (mmHg)	-12.4±9.5	-12.7±8.6	-16.2±8.9	-14.2±9.3	-10.1±11.7	-9.5±13.0	0.603	0.464	0.073
ΔDBP (mmHg)	-9.4±5.4	-11.6±6.0	-12.5±5.1	-9.3±4.5	-6.6±5.1	-5.0±7.6	0.948	0.023	0.001
ΔMBP (mmHg)	-10.4±5.8	-12.0±6.0	-13.7±5.0	-10.9±5.3	-7.8±7.0	-6.5±9.1	0.803	0.072	0.002
Variables	GG-nitrendipine			GT/TT-nitrendipine			P (GG versus GT/TT)		
	2W (16)	4W (16)	6W (16)	2W (9)	4W (9)	6W (9)	2W	4W	6W
Vist (N)									
ΔSBP (mmHg)	-17.1±12.8	-18.3±15.8	-23.3±13.0	-19.1±13.8	-17.2±8.8	-17.3±16.1	0.721	0.851	0.322
ΔDBP (mmHg)	-15.9±7.1	-15.4±9.4	-16.1±5.8	-9.9±9.1	-11.6±6.1	-12.7±9.1	0.077	0.286	0.266
ΔMBP (mmHg)	-16.3±8.4	-16.4±11.0	-18.5±7.7	-13.0±10.5	-13.4±6.2	--14.2±11.0	0.387	0.476	0.267



Note: the P-values were adjusted with age, BMI and gender.

Figure 1. Relationship between *eNOS* G874T polymorphism and the antihypertensive efficiency of dCCBs treatment after 6 weeks medication.

4. Discussion

Our study indicates that both azelnidipine and nitrendipine monotherapy can successfully reduced both SPB and DBP, as well as the TP, TBIL, CHO and LDL levels after 6 weeks of dCCB treatment. And our data shows that *eNOS* G894T polymorphism associated with therapeutic heterogeneity of

dCCB drugs.

Interesting, the results of our study suggest that CCBs treatment can significantly decrease TP, TBIL, CHO and LDL levels (P=0.017, P=0.045, P=0.039, P=0.041, respectively), which suggested that CCBs medication may have potential hepatoprotective activity and anti-atherosclerosis effects. Several researches had evidenced previously that azelnidipine exerts slight anti-atherogenic effect by reducing local oxidative stress^[28, 29], and the results of our study suggested that CCBs showed potential antiatherosclerosis effects by lowering CHO and LDL levels. Previous study evidenced that azelnidipine can significantly decrease both SU levels and the urinary uric acid to creatinine ration in hypertension patients^[30]. And there also data showed that nitrendipine was effective in stabilising most parameters of renal function in incipient diabetic nephropathy^[31] and had small but significant nephroprotective effect in renal-transplant patients^[32, 33]. And the results of our study were in line with previous researches that BU, Scr and UA levels were decreased, and the decrease change of BU and Scr levels in nitrendipine treatment group were significantly reduced than azelnidipine groups (P=0.02 and P=0.04 respectively). Based on these results we can estimate that dCCBs do had potential renoprotection effect in hypertension patients, and the renoprotection effect of

nitrendipine was stronger than azelnidipine.

The pharmacogenetic results of this research found that, of the polymorphisms we studied, only eNOS G894T polymorphism associated with antihypertensive effect, and this relationship only presented in azelnidipine treatment group. The hypotensive effects of azelnidipine was more sensitive in GG genotypes than GT or TT genotype carriers. Endothelial nitric oxide synthase (*eNOS*) is a limiting-velocity factor for endothelial cell to produce nitric oxide (NO), and it is expressed in many organs, such as cardiovascular system, brain, lung, liver and so on, where NO produced by this enzyme plays an important physiological role^[34, 35]. NO is a critical molecule in regulating the vascular system, and is involved in inhibiting the platelet aggregation and adhesion and reducing the cell proliferation of vascular smooth muscles^[36]. Clinical and animal studies had suggested that NO synthesis abnormal is a contributing factor for the pathogenesis of hypertension^[37, 38]. The eNOS G894T polymorphism, a coding region variant, results in a Glu298Asp substitution and decreases the NO levels^[39]. Azelnidipine is a long-acting CCB, it doesn't elicit reflex tachycardia during antihypertensive therapy by inhibits sympathetic nerve activity directly or indirectly^[40]. Evidence suggested that azelnidipine treatment could up-regulate the expression and activation of eNOS, while reduced ROS simultaneously increase NO availability^[28, 41]. Owing to the small number of subjects prescribed with nitrendipine in this study, we can not avoid the false negative errors of this result. The relationship between eNOS G874T polymorphism and nitrendipine hypotensive efficiency need further verification.

In summary, our study evidenced that dCCBs can successfully decrease BP and showed slight hepatoprotective activity and antiatherosclerosis effects. And our study evidenced for the first time that polymorphism of eNOS G894T was correlated with the antihypertensive efficiency of azelnidipine, the GG genotype carriers benefited more than GT/TT genotype carriers when under azelnidipine medication.

Acknowledgements

This work was supported by the National Scientific Foundation of China (No. 81273595, 30901834, 81001476), the Scientific Foundation of Hunan (No. 11K073, 10JJ4020), the "863" Project (No. 2012AA02A518) and NCET-10-0843. The study was supported by Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Hunan Key laboratory of Pharmacogenetics, Central South University, Changsha, Hunan. The authors also would like to thank the patients who participated in this study, without whom our research would not been possible to finish.

References

- [1] Chobanian A V, Bakris G L, Black H R, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. *JAMA*. 2003, 289(19): 2560-2572.
- [2] Xu B, Xu Z, Xu X, et al. Prevalence, awareness, treatment, and control of hypertension among residents in Guangdong Province, China, 2004 to 2007[J]. *Circ Cardiovasc Qual Outcomes*. 2013, 6(2): 217-222.
- [3] Sica D A. Pharmacotherapy review: calcium channel blockers[J]. *J Clin Hypertens (Greenwich)*. 2006, 8(1): 53-56.
- [4] Lederballe P O. Calcium blockade in arterial hypertension. Review[J]. *Hypertension*. 1983, 5(4 Pt 2): 174-179.
- [5] Tikhonov D B, Zhorov B S. Structural model for dihydropyridine binding to L-type calcium channels[J]. *J Biol Chem*. 2009, 284(28): 19006-19017.
- [6] Zhao Y, Zhai D, He H, et al. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort[J]. *Eur J Clin Pharmacol*. 2009, 65(6): 579-584.
- [7] Beitelshes A L, Navare H, Wang D, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response[J]. *Circ Cardiovasc Genet*. 2009, 2(4): 362-370.
- [8] Kamide K, Yang J, Matayoshi T, et al. Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers[J]. *Circ J*. 2009, 73(4): 732-740.
- [9] Sugimoto K, Katsuya T, Kamide K, et al. Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study[J]. *Int J Hypertens*. 2010, 2010: 196307.
- [10] Beitelshes A L, Navare H, Wang D, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response[J]. *Circ Cardiovasc Genet*. 2009, 2(4): 362-370.
- [11] Bremer T, Man A, Kask K, et al. CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension[J]. *Pharmacogenomics*. 2006, 7(3): 271-279.
- [12] Kamide K, Yang J, Matayoshi T, et al. Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers[J]. *Circ J*. 2009, 73(4): 732-740.
- [13] Liao P, Yu D, Lu S, et al. Smooth muscle-selective alternatively spliced exon generates functional variation in Cav1.2 calcium channels[J]. *J Biol Chem*. 2004, 279(48): 50329-50335.
- [14] Johnson A D, Newton-Cheh C, Chasman D I, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals[J]. *Hypertension*. 2011, 57(5): 903-910.
- [15] Huang P L, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase[J]. *Nature*. 1995, 377(6546): 239-242.
- [16] Hyndman M E, Parsons H G, Verma S, et al. The T-786-->C mutation in endothelial nitric oxide synthase is associated with hypertension[J]. *Hypertension*. 2002, 39(4): 919-922.

- [17] Kimura Y, Hirooka Y, Sagara Y, et al. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity[J]. *Clin Exp Hypertens*. 2007, 29(1): 13-21.
- [18] Wang C J, Zhao J B, Xu J L, et al. [Meta-analysis on the association of G894T polymorphism in endothelial nitric oxide synthase gene and essential hypertension in Chinese population][J]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2009, 30(8): 845-849.
- [19] Li Y Y. Endothelial nitric oxide synthase G894T gene polymorphism and essential hypertension in the Chinese population: a meta-analysis involving 11,248 subjects[J]. *Intern Med*. 2011, 50(19): 2099-2106.
- [20] Zintzaras E, Kitsios G, Stefanidis I. Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis[J]. *Hypertension*. 2006, 48(4): 700-710.
- [21] Jachymova M, Horky K, Bultas J, et al. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy[J]. *Biochem Biophys Res Commun*. 2001, 284(2): 426-430.
- [22] Kehrl J H, Sinnarajah S. RGS2: a multifunctional regulator of G-protein signaling[J]. *Int J Biochem Cell Biol*. 2002, 34(5): 432-438.
- [23] Semplicini A, Strapazzon G, Papparella I, et al. RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients[J]. *J Hypertens*. 2010, 28(5): 1104-1108.
- [24] Sugimoto K, Katsuya T, Kamide K, et al. Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study[J]. *Int J Hypertens*. 2010, 2010: 196307.
- [25] Semplicini A, Lenzini L, Sartori M, et al. Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II[J]. *J Hypertens*. 2006, 24(6): 1115-1124.
- [26] Wellington K, Scott L J. Azelnidipine[J]. *Drugs*. 2003, 63(23): 2613-2621, 2623-2624.
- [27] Furukawa T, Nukada T, Namiki Y, et al. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in *Xenopus* oocytes[J]. *Eur J Pharmacol*. 2009, 613(1-3): 100-107.
- [28] Noda K, Hosoya M, Nakajima S, et al. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice[J]. *Tohoku J Exp Med*. 2012, 228(4): 305-315.
- [29] Nakano K, Egashira K, Ohtani K, et al. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice[J]. *Atherosclerosis*. 2008, 196(1): 172-179.
- [30] Miyazaki S, Hamada T, Hirata S, et al. Effects of azelnidipine on uric acid metabolism in patients with essential hypertension[J]. *Clin Exp Hypertens*. 2014.
- [31] Kopf D, Schmitz H, Beyer J, et al. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy[J]. *Diabetes Nutr Metab*. 2001, 14(5): 245-252.
- [32] Rump L C, Oberhauser V, Schwertfeger E, et al. Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients[J]. *J Hypertens*. 2000, 18(8): 1115-1119.
- [33] Rahn K H, Barenbrock M, Fritschka E, et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial[J]. *Lancet*. 1999, 354(9188): 1415-1420.
- [34] Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace[J]. *Circulation*. 2006, 113(13): 1708-1714.
- [35] Ortiz P A, Garvin J L. Trafficking and activation of eNOS in epithelial cells[J]. *Acta Physiol Scand*. 2003, 179(2): 107-114.
- [36] Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace[J]. *Circulation*. 2006, 113(13): 1708-1714.
- [37] Huang P L, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase[J]. *Nature*. 1995, 377(6546): 239-242.
- [38] Hyndman M E, Parsons H G, Verma S, et al. The T-786-->C mutation in endothelial nitric oxide synthase is associated with hypertension[J]. *Hypertension*. 2002, 39(4): 919-922.
- [39] Veldman B A, Spiering W, Doevendans P A, et al. The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide[J]. *J Hypertens*. 2002, 20(10): 2023-2027.
- [40] Huang B S, Leenen F H. Sympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats[J]. *J Cardiovasc Pharmacol*. 2003, 42(2): 153-160.
- [41] Kimura Y, Hirooka Y, Sagara Y, et al. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity[J]. *Clin Exp Hypertens*. 2007, 29(1): 13-21.